Date posted: 14 October 2024
BRISTOL, UK, 14th October 2024.
We were honoured to welcome UK Science Minster Lord Patrick Vallance into our Bristol lab last week during his trip to Bristol for the Regional Investment and Health & Life Sciences Summit.
He had a great discussion with one of our scientific founders and CSO Ash Toye about Scarlet’s pioneering red blood cell-based platform technology and our belief that the future of medicine is in our blood. Thanks to the team at SCVC for facilitating the visit.
Ash Toye, CSO of Scarlet Therapeutics, said: “Lord Vallance and I enjoyed a fascinating and important conversation about the challenges faced by spinouts in the UK, the funding landscape here both here in the UK and globally, and the possibilities our red blood cell platform could offer. It was a wonderful opportunity to meet Lord Vallance and share our vision with him.”
Image courtesy of Science Creates
For press enquires please contact
Alistair Irvine
Tel: +44 75077 86615
Email: press@scarlet-tx.com
Website: www.scarlet-tx.com
LinkedIn: Scarlet Therapeutics Ltd | LinkedIn
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, which have many advantageous qualities including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the RBC which are shielded from the immune system. Born out of more than a decade of research at the University of Bristol and the learning from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.